PHASE II STUDY OF PEMBROLIZUMAB PLUS SURVAXM FOR GLIOBLASTOMA AT FIRST RECURRENCE

被引：0
|
作者：
Ahluwalia, Manmeet [1 ]
Peereboom, David [1 ]
Rauf, Yasmeen [2 ]
Schilero, Cathy [1 ]
Ciolfi, Marci [1 ]
Ciesielski, Michael [3 ]
Fenstermaker, Robert [4 ]
机构：
[1] Cleveland Clin, Main Campus, Cleveland, OH 44106 USA
[2] Cleveland Clin, Dublin, OH USA
[3] Roswell Pk, Buffalo, NY USA
[4] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
来源：
NEURO-ONCOLOGY | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CTIM-10
引用
收藏
页码：34 / 35
页数：3
相关论文
共 50 条
  • [1] Phase II study of pembrolizumab plus SurVaxM for glioblastoma at first recurrence.
    Ahluwalia, Manmeet Singh
    Peereboom, David M.
    Ciolfi, Marci
    Schilero, Cathy
    Hobbs, Brian
    Ciesielski, Michael J.
    Fenstermaker, Robert Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Ahluwalia, Manmeet
    Ciesielski, Michael J.
    Reardon, David A.
    Abad, Ajay
    Curry, William
    Wong, Eric
    Peereboom, David
    Figel, Sheila
    Hutson, Alan
    Groman, Adrienne
    Withers, Henry
    Liu, Song
    Belal, Ahmed
    Qiu, Jingxin
    Mogensen, Kathleen
    Schilero, Cathy
    Khosla, Atulya
    Casucci, Danielle
    Mechtler, Laszlo
    Fenstermaker, Robert
    NEURO-ONCOLOGY, 2022, 24 : 66 - 66
  • [3] PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS
    Reardon, David
    Molinaro, Annette
    Peters, Katherine
    Clarke, Jennifer
    Jordan, Justin
    de Groot, John
    Nghiemphu, Phioanh
    Kaley, Thomas
    Colman, Howard
    McCluskey, Christine
    Smith, Timothy
    Cote, David
    Severgnini, Mariano
    Yearley, Jennifer
    Zhao, Qing
    Blumenschein, Wendy
    Duda, Gabriel
    Muzikansky, Alona
    Jain, Rakesh
    Wen, Patrick
    Nayak, Lakshmi
    NEURO-ONCOLOGY, 2020, 22 : 40 - 40
  • [4] Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients
    Reardon, David A.
    Nayak, Lakshmi
    Peters, Katherine B.
    Clarke, Jennifer Leigh
    Jordan, Justin T.
    De Groot, John Frederick
    Nghiemphu, Phioanh Leia
    Kaley, Thomas Joseph
    Colman, Howard
    Gaffey, Sarah C.
    Caruso, Victoria
    Debruyne, Myriam Bednarek
    Bhavsar, Chinmay
    Molinaro, Annette M.
    Smith, Timothy
    Severgnini, Mariano
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
    Ahluwalia, Manmeet S.
    Reardon, David A.
    Abad, Ajay P.
    Curry, William T.
    Wong, Eric T.
    Figel, Sheila A.
    Mechtler, Laszlo L.
    Peereboom, David M.
    Hutson, Alan D.
    Withers, Henry G.
    Liu, Song
    Belal, Ahmed N.
    Qiu, Jingxin
    Mogensen, Kathleen M.
    Dharma, Sanam S.
    Dhawan, Andrew
    Birkemeier, Meaghan T.
    Casucci, Danielle M.
    Ciesielski, Michael J.
    Fenstermaker, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (07) : 1453 - +
  • [6] Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
    Iwamoto, Fabio M.
    Tanguturi, Shyam K.
    Nayak, Lakshmi
    Wang, Tony J.
    Desai, Arati
    Lustig, Robert A.
    Bagley, Stephen
    Wong, Eric T.
    Hertan, Lauren M.
    Mccluskey, Christine
    Hayden, Julia
    Muzikansky, Alona
    Nakhawa, Shreya
    Japo, Julia
    Bossi, Connor C.
    Meylan, Maxime
    Tian, Ye
    Barlow, Graham L.
    Speliakos, Paul
    Ayoub, Georges
    Meredith, David M.
    Ligon, Keith L.
    Haas-Kogan, Daphne
    Huang, Kun
    Wucherpfennig, Kai W.
    Wen, Patrick Y.
    Reardon, David A.
    CLINICAL CANCER RESEARCH, 2025, 31 (02) : 316 - 327
  • [7] Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
    Nayak, Lakshmi
    Molinaro, Annette M.
    Peters, Katherine
    Clarke, Jennifer L.
    Jordan, Justin T.
    de Groot, John
    Nghiemphu, Leia
    Kaley, Thomas
    Colman, Howard
    McCluskey, Christine
    Gaffey, Sarah
    Smith, Timothy R.
    Cote, David J.
    Severgnini, Mariano
    Yearley, Jennifer H.
    Zhao, Qing
    Blumenschein, Wendy M.
    Duda, Dan G.
    Muzikansky, Alona
    Jain, Rakesh K.
    Wen, Patrick Y.
    Reardon, David A.
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 1048 - 1057
  • [8] PHASE II STUDY OF IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH A FIRST RECURRENCE OF GLIOBLASTOMA
    Aoki, T.
    Arakawa, Y.
    Ueba, T.
    Miyatake, S.
    Nozaki, K.
    Taki, W.
    Tsukahara, T.
    Miyamoto, S.
    Matsutani, M.
    NEURO-ONCOLOGY, 2012, 14 : 39 - 39
  • [9] PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Ahluwalia, Manmeet
    Reardon, David
    Abad, Ajay
    Curry, William
    Wong, Eric
    Peereboom, David
    Belal, Ahmed
    Qiu, Jingxin
    Mogensen, Kathleen
    Schilero, Cathy
    Casucci, Danielle
    Mechtler, Laszlo
    Uhlmann, Erik
    Ciesielski, Michael
    Fenstermaker, Robert
    NEURO-ONCOLOGY, 2018, 20 : 10 - 11
  • [10] PHASE II STUDY OF IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH A FIRST RECURRENCE OF GLIOBLASTOMA MULTIFORME
    Aoki, T.
    Ueba, T.
    Takahashi, J.
    Miyatake, S.
    Nozaki, K.
    Taki, W.
    Matsutani, M.
    NEURO-ONCOLOGY, 2010, 12 : 48 - 48
12345